Editorial comment

摘要

This study presents some very interesting findings on several fronts. Firstly it points out that the practice of restaging trans-urethral resection (TUR), which is recommended at least for stage Tl tumors in almost all published guidelines for bladder cancer, is not as widely practiced as one would hope (7.9% of stage Tl patients underwent re-TUR within 60 days). The second finding is that restaging TUR yields a long-tefm survival benefit not only for those with Tl disease but for those with T2 disease! The later observation is befuddling to say the least.